rorenin, the inactive precursor of renin, circulates in human plasma in excess of renin, at concentrations that are up to 100 times higher. 1 The reasons for this are unknown, but an attractive concept is that circulating prorenin is taken up at tissue sites where it contributes, after its local activation to renin, to tissue angiotensin production. Evidence for this concept comes from studies in transgenic animals displaying (inducible) prorenin expression. 2, 3 Prorenin activation at tissue sites might involve proteolytic removal of its prosegment. 4 Alternatively, activation could occur in a nonproteolytic manner, for instance, through binding to a receptor. Indeed, Ichihara et al 5 have proposed recently that human prorenin has so-called gate and handle regions for nonproteolytic activation. According to this concept, the handle region interacts with a putative receptor, which subsequently leads to unfolding of the gate region from the renin molecule. In vivo treatment with a decoy peptide corresponding to the gate region reduced the renal content of angiotensin (Ang) I and II in streptozotocin-induced diabetic rats, thereby supporting, for the first time, tissue Ang production by endogenous prorenin.
Interestingly, Nguyen et al 6 have cloned a (pro)renin receptor, which exactly fulfills the above description, because prorenin binding to this receptor allowed prorenin to become fully enzymatically active in a nonproteolytic manner. Unexpectedly, (pro)renin binding to this receptor in glomerular mesangial cells also induced angiotensin-independent effects, that is, an increase in DNA synthesis, activation of the mitogen-activated protein kinases (MAPKs) extracellular signal regulated kinase 1 (p44)/extracellular signal regulated kinase 2 (p42), and plasminogen-activator inhibitor (PAI)-1 release, 6, 7 thus leading the authors to suggest that prorenin acts as an agonist of this receptor.
Prorenin, a phosphomannosylated protein, also binds to mannose 6-phosphate/insulin-like growth factor II receptors (IGF2R). Binding to these receptors is followed by internal-ization, intracellular proteolytic cleavage to renin, and subsequent proteolytic/hydrolytic removal or clearance. 4 Although prorenin binding to IGF2R did not result in Ang generation, 8 it is still possible that prorenin, like other M6P-containing proteins, acts as an agonist of IGF2R.
In the present study, we set out to investigate the angiotensin-independent effects of prorenin in neonatal rat cardiomyocytes using a gene transcription profiling approach. Cardiomyocytes were chosen not only because they express IGF2R 4 but also because transgenic rats expressing prorenin exclusively in the liver (resulting in a 400-fold rise in plasma prorenin) display severe cardiac hypertrophy in the absence of hypertension. 2 We verified the expression of the recently cloned (pro)renin receptor in cardiomyocytes. Finally, we evaluated the previously reported, angiotensin-independent, effects of prorenin mediated through this receptor.
Methods

Cell Culture
All of the experiments were performed according to the regulations of the Animal Care Committee of the Erasmus MC in accordance with the Guiding Principles of the American Physiological Society. Primary cultures of neonatal Wistar rat (Harlan) cardiomyocytes were prepared as described before. 4 Cells were serum deprived for 24 hours, rinsed 3 times with 1 mL of warm (37°C) PBS, and incubated for a maximum of 48 hours at 37°C with 1 mL of serum-free medium, supplemented with 1% BSA, and containing 100 U/L (Ϸ2 nmol/L) of recombinant human prorenin 4 and/or 150 nmol/L of human angiotensinogen (Sigma) in the presence or absence of M6P, eprosartan, PD123319, aliskiren (a gift of Novartis, Basel, Switzerland) or SB203580 (Sigma) to block IGF2R, angiotensin II type 1 (AT 1 ) receptors, angiotensin II type 2 (AT 2 ) receptors, renin, and p38 MAPK, respectively. For comparison, experiments with 1000 U/L of prorenin, 100 U/L of nonglycosylated prorenin, 9 100 nmol/L of Ang II (Bachem), or 100 nmol/L of endothelin-1 (ET-1; Sigma) were also performed. Cells incubated without (ant) agonists served as control. At the end of each experiment, cells and medium were collected and stored at Ϫ70°C.
(Pro)renin Receptor Expression
Cardiomyocytes were lysed in Laemmli loading buffer (LLB). Skeleton protein-deprived fractions were obtained by centrifugation at 7000g for 30 minutes at 4°C. Fractions were boiled for 3 minutes, separated (20 g) by SDS-PAGE (12%), and blotted to polyvinylidene fluoride membranes (Immunblot, Biorad). Equal protein distribution was assessed by Ponceau Red staining. Next, membranes were incubated overnight at 4°C with antibody SE3148 (a gift of Dr G. Nguyen, Collège de France, Paris, France), diluted 1:7500 in 150 mmol/L of NaCl buffered with 10 mmol/L of Tris and containing 0.1% Tween 20 (TTBS) and 0.5% milk powder after blocking nonspecific binding using the same buffer for 1 hour at room temperature. Receptor signal was visualized using a horseradish peroxidase-conjugated anti-rabbit antibody, SuperSignal WestFemto reagent (Pierce), and Hyperfilm ECL (Amersham Biosciences). To localize the receptor, cardiomyocytes were grown on glass cover slips at 3ϫ10 4 cells/cm 2 , rinsed twice with cold PBS, fixed with 3% paraformaldehyde, permeabilized using 0.3% Triton X-100 in PBS, and blocked with 1% BSA in 0.1% Tween 20 containing PBS. Cells were then exposed to antibody SE3148 (1:500 in PBS with 0.1% Tween 20) for 1 hour at 37°C followed by overnight incubation at 4°C and subsequently incubated with biotinylated goat-anti-rabbit antibody (1:100) for 30 minutes at room temperature and tetramethylrhodamine B isothiocyanate-streptavidin (1:40) for 15 minutes at room temperature, both in PBS with Tween 20. Phalloidin-fluorescein isothiocyanate (15 ng/mL in PBS, 4 hours) was applied to stain actin filaments. Images were obtained with a Zeiss LSM-510 NLO confocal microscope system.
Biochemical Measurements
PAI-1 was measured with a sandwich ELISA using monoclonal antibodies specific for rat PAI-1 (a gift of P. Declerck, Katholieke Universiteit Leuven, Leuven, Belgium). 10 MAPK activation was assessed by Western blotting, using cells lysates (20 g) in LLB and antibodies specific for total and phosphorylated p42, p44, or p38 MAPK (Cell Signaling, 1:1000 in TTBS containing 75 mmol/L of NaCl and 0.5% milk powder for 4 hours at 20°C). Iodinated secondary antibodies (Amersham, 1:5000) were detected using a phosphor imager system (Biorad).
HSP27 phosphorylation was assessed by Western blotting using cell lysates (20 g) in LLB, phospho-HSP27-Ser82 antibody (Cell Signaling, 1:1000 in TTBS containing 150 mmol/L of NaCl and 0.5% milk powder overnight at 4°C), and West Femto reagents. 11 Quantification was done by densitometry with local background subtraction.
Gene Transcription Analysis
Cardiomyocytes were lysed using Tri-Reagent (Sigma-Aldrich). Individual purified RNAs were checked using Agilent Laboratoryon-Chip analysis (Agilent Bioanalyzer 2100) and UV spectrum analysis, equimolar pooled, amplified (Ambion), and Cye3 or Cye5 labeled, as described. 12 Rat gene microarray slides representing Compugen/Laboratory-on-web 4.8-K oligonucleotide library in triplo were hybridized in a dye-swap loop protocol. Spot intensity measurement and global background (mean intensity plus 2ϫSD of 750 buffer-only spots) subtraction was performed within GenepixPro. Data files were uploaded in Rosetta Resolver for normalization, intensity ratio calculation, and confidence call estimation per gene or extracted with MS Excel, followed by variance stabilized normalization (VSN) in R and SAM analysis per individual spot. 13, 14 Original data files are accessible at National Center for Biotechnology Information (NCBI) Gene Expression Omnibus through Acc.ID GSE4340. Gene network building was performed using Ingenuity (www.ingenuity.com) software. For gene annotations, the National Institutes of Health Rat Genome Database Portal (http://rgd. mcw.edu/), NCBI Entrez (www.ncbi.nlm.nih.gov/gquery), and iHOP (www.pdg.cnb.uam.es/UniPub/iHOP) were used.
Quantitative Real-Time RT-PCR
Transcription of selected genes was quantified using intron-spanning assays on an ABI 7700 (Applied Biosystems Inc) using exon junction-specific probes 15 or SYBR green chemistry for Col3a1 (forward: 5ЈAGGTCCTGCGGGTAACAST, reverse: 5ЈACTT-TCACCCTTGAYACCCTG). 16 Superscript (0.2 U/mL), random hexamers (2.5 mol/L), and RNAsin (0.5 U/mL; Promega) were used to transcribe 1 g of RNA to cDNA in 30 L for 60 minutes at 42°C. cDNAs were stored at Ϫ70°C and diluted 1:5 in H 2 O, and PCR reactions were performed with 5 L of diluted cDNA in 25-L reactions. Expression level was determined by threshold cycle number (C T ) and, using the delta delta C T method, normalized against GAPDH and compared relative to the control in concordance with the manufacturer's instructions. 15 
Statistical Analysis
Data are expressed as meanϮSEM. Rosetta Resolver and Graphpad Prism were used for statistical analysis. PϽ0.05 was considered significant.
Results (Pro)renin Receptor Expression
Western hybridization revealed (pro)renin receptor expression in the cytosol/microsome fraction of cardiomyocytes ( Figure 1 ). Expression in the cytoskeleton fraction was close to the detection limit. Expression was also present in adult rat heart and brain homogenates. The cardiomyocyte cytoskeleton fraction contained a second band, which was not further investigated because of its low expression. Confocal microscopy results are in agreement with low plasma and high vesicular membrane staining of the receptor ( Figure 1 ). Staining was absent after deletion of the primary antibody (data not shown).
PAI-1 Secretion and MAPK Activation
Prorenin plus angiotensinogen increased PAI-1 secretion to the same degree as Ang II (nϭ7 for all; Figure 2A ), and this effect was blocked by 1 mol/L of eprosartan but not 1 mol/L of PD123319 or 10 mmol/L of M6P. When added separately, none of the receptor blockers (data not shown), prorenin, or angiotensinogen affected PAI-1 release significantly.
Prorenin (100 U/L) increased p38 MAPK but not p42 MAPK or p44 MAPK phosphorylation (nϭ5; Figure 2B ). Peak p38 MAPK phosphorylation levels were reached after 45 minutes. ET-1 (nϭ5) activated all of the MAPKs at tϭ15 minutes. Phosphorylation of p38 MAPK at 1000 U/L of prorenin was 1.9Ϯ0.3 times (nϭ3) higher (Pϭ0.03) than at 100 U/L, and nonglycosylated prorenin (100 U/L) increased p38 MAPK phosphorylation to the same degree as wild-type prorenin (to 201Ϯ23% of control; nϭ3).
Gene Expression Profiling and Validation
RNA was isolated from 5 separate experiments after 4 hours of stimulation with prorenin, Ang II, or vehicle (control). To obtain estimates of differential expression with equal precision between all of the samples (prorenin versus control, Ang II versus control, and prorenin versus Ang II), all of the possible sample pairs were cohybridized to the same array and dye replicated. Image analysis, filtering for genes with no detectable expression, and processing of backgroundcorrected intensities with the Rosetta Resolver error model resulted in 4619 genes being amenable for comparison in all 3 combinations. The results of the pairwise comparisons (PϽ0.001) are given in Figure 3A and supplemental Table I (available online at http://hyper.ahajournals.org). In the prorenin versus control, Ang II versus control, and prorenin versus Ang II comparisons, respectively, 260, 215, and 177 genes were differentially expressed. Of these genes, 43%, 41%, and 12% were upregulated and displayed an absolute fold change of Ն1.3. Comparable results were obtained when the data were analyzed with a different normalization algorithm (VSN) 14 followed by SAM analysis 13 (data not shown). Histogram analysis of the expression ratios ( Figure 3B ) revealed a more pronounced increase in number and activation of prorenin-responding genes as compared with Ang II-responding genes (Mann-Whitney test, Pϭ0.0002).
To obtain a more robust set of prorenin-specific genes, the data were also analyzed by 1-way ANOVA (PϽ0.01). This resulted in 171 genes displaying differential expression between the 3 conditions, of which 91, 23, and 36 overlapped with the 3 above pairwise comparisons, respectively. The Table shows the 28 genes that were also not regulated by Ang II, that is, the truly "prorenin-specific" genes.
Seven genes (Opg, Timp1, Best5, Hsp27, pro-Anp [Nppa], Col3a1, and Hk2) were selected for further validation of the microarray data. Selection was based on magnitude of induction (eg, Best5) and/or cardiovascular relevance (eg, Timp1). Two of these genes were prorenin specific (Hsp27 and Hk2). Quantitative real-time RT-PCR on individual mRNAs (Figure 3C ) and RNA pools (rϭ0.72; Pϭ0.004; Figure 3D ) confirmed the microarray results for these 7 genes. Because of large interindividual variation for Best5, the prorenininduced effects on this gene were not significant when based on measurements in individual samples. Figure 4A shows the time course of gene regulation of the 7 selected genes during stimulation with prorenin. In most cases, the peak levels observed after 4 hours had returned to baseline after 24 hours.
To investigate the Ang II dependency of the effect of prorenin, the 4-hour incubation experiments with prorenin were repeated in the presence of 1 mol/L of eprosartan (nϭ3) or 100 nmol/L of aliskiren (nϭ5). Neither drug blocked the effects of prorenin on the 7 genes ( Figure 4B ) nor did these drugs exert effects when added alone (data not shown).
Pathway Analysis
Uploading the 91 prorenin-regulated genes (resulting from the overlap between the pairwise comparison and the ANOVA) in Ingenuity allowed the construction of a backbone network of 140 genes (supplemental Figure I) , derived by merging 4 main clusters. Of these genes, 58 were present on the array, and 51 of these 58 genes were affected by prorenin. Including all 187 genes that were regulated by prorenin but not Ang II according to the pairwise comparison ( Figure 3A) did not result in a larger network but increased the number of small gene clusters (containing Ͻ4 genes; data not shown). Mapping of prorenin-regulated genes into functional groups in Ingenuity revealed the involvement of 17 genes in "Cellular Assembly and Organization," 5 in "Cellular Movement," 17 in "Nervous System Development and Function," and 7 in "Protein Trafficking" (PϽ0.001, exact Fisher test; supplemental Table II) . 
Transcription Factor Binding-Site Motif Frequency Distribution Analysis and Identification
Data were uploaded in the TELIS database (www.telis. ucla.edu) 17 to find common transcription factor binding-site motifs (TFBMs) among the 187 of 260 genes that were regulated by prorenin but not Ang II. Using stringent criteria (NCBI_Refseq [Fall 2003 ], 300 nucleotide rat promotor sequences, homology stringency 0.95; PϽ0.005; false discovery rate 20%), the following TFBMs (representing 28 different genes, supplemental 
Genes Confined to Cardiovascular QTL Regions
Ninety-six genes of the Compugen 4.8-K oligonucleotide library were positioned within cardiovascular QTL regions as retrieved from the TIGR Rat Gene Index (www.tigr.org/tdb/tgi/ resourcerer/rat_qtl.shtml). Prorenin regulated 13 of these 96 independent genes (PϽ0.0001, exact Fisher test; supplemental Table I ), including Synthaxin-7 (Stx7, see TFBM analysis and supplemental Figure I ) and Arginase-1 (Arg1) on rat chromo- 
Prorenin-Specific Genes
p38 MAPK Pathway
Activation of p38 MAPK has been reported to influence actin filament dynamics via MAPK-activated protein kinase 2 (MK2) and HSP27 activation. 18 The prorenin-induced increases in mRNAs of cytokines that are known to be stimulated by MK2 (Il-1a, Il-1b, Mip3␣/Scya20, and Ccl3/Mip1␣/Scya3) 19, 20 support the activation of this pathway by prorenin. HSP27 (Ser-82) phosphorylation measurements confirm prorenin-induced HSP27 activation in cardiomyocytes ( Figure 5A ). HSP27 phosphorylation peaked at 45 minutes (nϭ3, data not shown), occurred in a concentrationdependent manner, and was blocked by SB203580. Finally, 2D proteomic differential display experiments, performed on cardiomyocytes after 48 hours of prorenin stimulation, reveal 2D positional shifts and up/downregulation of, among others, actin protein spots. Figure 5B shows the identification of one of the actin protein spots selected for confirmation of identity. Alterations in actin filament dynamics were also reflected at the mRNA level, as 29% and 40% of genes with annotations containing "actin" or "LIM" (eg, Csrp3/Mlp) were regulated by prorenin (PϽ0.0001, Fisher's exact test). LIM (Pfam-PF00412) was incorporated in this analysis, because LIM-domain containing proteins are known to interact with actin. 21 The prorenin-induced upregulation of St2 (Јc-FOS_respon-sive_gene-1Ј/Il1rl1) corroborates c-Fos activation by p38 MAPK. 22
Renin-Ang System Genes and Ang II-Regulated Genes
Prorenin did not regulate renin-Ang system genes (including the IGF2R). In support of PAI-1 antigen release results, Pai1 (10ϫPR), and 100 U/L of nonglycosylated prorenin (ngPR) with or without SB203580 for 45 minutes. Bottom, representative experiment. *PϽ0.05 vs control (ie, cells without PR or SB203580). B, Actin cytoskeleton changes in cardiomyocytes after a 48-hour incubation with 100 U/L of prorenin or 100 nmol/L of Ang II. Cell lysates were exposed to isoelectric focusing (pI 3 to 10, linear) and SDS-PAGE (10%) separation, followed by Commassie Brilliant-Blue staining. Gels were scanned and aligned in Syquest (Biorad) to quantify differential expression of proteins. 11 Selected protein spots were excised, trypsin digested, and subjected to matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry for protein identification. Peptide mass fingerprints were analyzed using the Mascott protein database (www.matrixscience.com) and the Mowse score automatic cutoff. Protein spot 3421 (boxed) was identified as actin. Top, composite image of the 3 scans (using letter labeling for aligned spots) simultaneously displays the relative density of spot 3421 in control, Ang II-treated, and prorenin-treated cells. Arrows in the control panel indicate differentially displayed actin protein spots.
mRNA levels were stimulated by Ang II but not prorenin. Ang II also regulated interleukin 6, atrial natriuretic peptide, and the adrenomedullin-related genes receptor activitymodifying protein-3 (Ramp3) and adrenomedullin precursor (Adm) in full agreement with previous investigations in cardiomyocytes. [23] [24] [25] 
Discussion
This study shows that recombinant human prorenin induces gene transcription in neonatal rat cardiomyocytes independently of Ang II generation. Human prorenin-induced Ang generation in these cells is highly unlikely, not only because of the species specificity of the renin-angiotensinogen reaction 26 but also because our prorenin preparation contains very little (Ͻ2%) renin activity. 4 Furthermore, angiotensinogen protein expression, if occurring in neonatal rat cardiomyocytes, is low. 26 Indeed, in a previous study, we were unable to detect Ang generation by these cells after the addition of human prorenin to the medium. 8 Finally, neither the renin inhibitor aliskiren nor the AT 1 receptor antagonist eprosartan blocked the transcriptional effects of prorenin, thereby confirming that neither renin activity nor AT 1 receptor stimulation are required for these effects.
If not involving Ang II, alternative mechanisms must be provided to explain the prorenin-induced regulation of gene transcription. Recent investigations support the existence of 2 prorenin-binding receptors coupling directly to second messenger systems: IGF2R, which serve as G protein-coupled receptors when exposed to M6P-containing proteins like prorenin, 27 and (pro)renin receptors, which activate p42/p44 MAPK and release PAI-1 after exposure to (pro)renin. 6, 7 IGF2Rs are abundantly present in neonatal rat cardiomyocytes. 4 The present study now shows that cardiomyocytes also express the (pro)renin receptor, although at low levels. Expression seemed to occur largely intracellularly. Although this contrasts with the cell surface location that was originally proposed in mesangial cells, it is consistent with the fact that the C-terminal tail of the (pro)renin receptor is identical to the M8-9/Atp6ap2 protein, which associates with the vacuolar H ϩ -ATPase (V-ATPase) complex. 28 The (pro)renin receptor antibody used in the present study (SE3148) was generated with an immunization peptide that overlapped the M8 -9 sequence. 6 V-ATPases maintain pH gradients between intracellular compartments and the cytoplasm by proton secretion, 28 and, thus, prorenin might exert effects by interfering with this process.
Prorenin application to cardiomyocytes did not result in detectable p42/p44 MAPK activation or PAI-1 release as in human mesangial cells. 6, 7 Thus, either the expression of (pro)renin receptors in cardiomyocytes is too low, or their (intracellular) location does not allow such effects. PAI-1 release did occur when applying prorenin in combination with human angiotensinogen. Eprosartan, but not PD123319 or M6P, blocked this effect. Thus, in cardiomyocytes, unlike mesangial cells, PAI-1 release is entirely dependent on Ang generation and subsequent AT 1 receptor activation. It does not require IGF2R. The Ang II-induced upregulation of Pai-1 expression complements this view.
Independently of Ang II generation (ie, in the absence of angiotensinogen), prorenin was found to activate p38 MAPK in cardiomyocytes. This effect occurred in a concentrationdependent manner and could be mimicked by nonglycosylated prorenin. The latter suggests that it does not involve IGF2R, thereby excluding a scenario in which the stimulation of intracellular (pro)renin receptors depends on IGF2R-mediated internalization of prorenin. 29 Consequently, it seems that prorenin activates the p38 MAPK pathway in an IGF2R-independent manner, for instance, through direct stimulation of (pro)renin receptors.
Gene transcription profiling studies support and extend this view. Not only did these studies confirm prorenin-induced activation of the p38 MAPK pathway, evidenced by the stimulation of its downstream (MK2-and c-FOS-dependent) targets HSP27, Il-1a, Il-1b, Scya20, Ccl3/Mip1␣/Scya3, and St2, 19, 20, 22 but they also reveal that prorenin regulates genes confined to cardiovascular QTL regions that are not necessarily linked to p38 MAPK activation. Regulation occurred in a time-dependent manner, with peak changes obtained after 4 hours of prorenin exposure. Overrepresentation of genes containing binding site motifs for the transcription factors Elk1, Ets1, Ap1, and Nrf2 (known effectors of the p38 MAPK pathway) 30 -32 further corroborates prorenin-induced p38 MAPK activation. It should be noted that Ang II also activates p38 MAPK in neonatal rat cardiomyocytes. 33 This explains, at least in part, the overlap between prorenin-and Ang II-induced genes.
Renin-Ang system gene regulation was not observed after prorenin exposure, in agreement with the concept that the prorenin-induced effects occur in an Ang II-independent manner. Prorenin-induced p38 MAPK activation coincided with HSP27 phosphorylation, and the latter phenomenon was blocked by the p38 MAPK inhibitor SB203580. HSP27, through its regulation of actin filament dynamics, is believed to be involved in maintaining the integrity of cell architecture, growth, motility, survival, and death. 34 Proteome differential display experiments performed on cardiomyocytes after 48 hours of prorenin stimulation support the downstream effects of HSP27 on the actin cytoskeleton, as does the overrepresentation of actin-related genes regulated by prorenin, like the LIM domain containing Csrp3/Mlp. The p38 MAPK-MK2 signaling pathway, involving both HSP27 and LIM-kinase 1, has also been linked to VEGFinduced actin reorganization in endothelial cells. 21 Furthermore, in view of the observation that the (pro)renin receptor equals a subunit of the V-ATPase complex, 28 V-ATPase transport might be responsible for the reorganization of actin cytoskeleton. 35 In fact, V-ATPase-induced acidosis is sufficient to activate p38 MAPK and HSP27. 36, 37 
Perspectives
The current data support prorenin-induced intracellular signaling in cardiomyocytes. This effect occurred independently of Ang II and IGF2R. The exact mechanism underlying this phenomenon is not yet known. One possibility is that it involves the recently discovered (pro)renin receptor. Our data suggest that prorenin directly affects cardiac growth and development, thereby providing an explanation for the Ang II-and blood pressure-independent cardiovascular damage observed in rats overexpressing prorenin. 2 Consequently, the rise in prorenin in diabetes, particularly in subjects with microvascular complications, 1 might be of functional relevance. Combined with the recent concept that prorenin becomes activated when bound to the (pro)renin receptor, 5, 6 a new class of drugs might emerge, that is, (pro)renin receptor blockers, which prevent both Ang generation at tissue sites and prorenin-induced, angiotensin-independent effects.
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